Antihaemorrhagics and procoagulants and haemostatatic agents and antifibrinolytic agents (A61P7/04)

A   Human necessities(312083)
A61P7/04                     Antihaemorrhagics; procoagulants; haemostatatic agents; antifibrinolytic agents(137)
eans with systemic hemostatic effect // 2640131
FIELD: pharmacology.SUBSTANCE: application of calcium bis(2-aminoethane-1-sulfonate) as a means of systemic hemostatic effect is proposed.EFFECT: application of the invention extends the arsenal of biologically active substances, including those with a systemic hemostatic effect; the compound exhibits an effective hemostatic effect due to proaggregant activity as compared to ethamylate.2 tbl
ethod for treatment of heavy liver lesion with posttraumatic coagulopathy // 2639422
FIELD: medicine.SUBSTANCE: right gastro-omental vein is excised and catheterized, through which fresh frozen plasma and platelet concentrate in a ratio of 1:1 or fresh platelet-rich plasma is transfused into the portal vein system with additional administration of 1 g tranexamic acid for 10 minutes and further administration every 8 hours for 1 g till hyperfibrinolysis reduction. Treatment is carried out under the control of thromboelastography, aggregation, APTT, PT, MHO and fibrinogen level.EFFECT: method allows to achieve maximum hemostatic effect in the wound, to correct the key pathogenetic links of post-traumatic coagulopathy and to reduce the risk of early and distant complications.1 cl
Hemostatic coating in form of sponge or film (versions) // 2639379
FIELD: pharmacology.SUBSTANCE: invention is a hemostatic coating in the form of a sponge or film containing a base and an active substance zeolite, characterized by containing sodium alginate, a plasticizer and water as the base, and natural zeolite (Na2+, K2+)O⋅Al2O3⋅8SiO2⋅10H2O as an active substance, and the components in the hemostatic coating are in a certain ratio, in wt %.EFFECT: expanded assortment of hemostatic sponges and films with pronounced hemostatic action and a significant decrease in the temperature of tissues at the place of agent contact with the wound surface.4 cl, 25 ex

Procoagulant peptides, their derivatives and their application // 2635510
FIELD: medicine.SUBSTANCE: group of inventions includes a hemostatic material comprising a peptide having the sequence of SEQ ID NO: 1 or its sequence of amino acid analogs and a framework where the said framework is a natural gelatin polymer, wherein the gelatin comprises an absorbable hemostatic powder matrix, a sponge matrix, a pasty matrix , a gel matrix or combinations thereof, and the said gelatin is cross-linked and has the form of particles with a liquid carrier, as well as a material for tissue healing anal and a method for hemostatic treatment or tissue healing at the wound site, comprising formation of a hemostatic material or tissue healing material of a similar composition and application of a hemostatic material or tissue healing material to the wound site.EFFECT: expanded arsenal of technical means of hemostatic purpose, which can successfully work in heparinized blood.33 cl, 8 dwg, 1 tbl, 10 ex

Hemostatic material, hemostatic means and material based thereon // 2635465
FIELD: medicine.SUBSTANCE: material comprising a hemostatic agent O,O'-dipalmitoyl chitosan or a salt thereof and one or more bioadhesive neutral substances are described.EFFECT: increased hemostatic activity of modified chitosan, hydrophobically modified chitosan, high water solubility, increased hemostatic properties of the hemostatic material based on modified chitosan, expansion of the hemostatic arsenal.28 cl, 7 tbl, 1 dwg, 11 ex
ethod for endoscopic treatment of ulcerous gastroduodenal bleeding // 2633588
FIELD: medicine.SUBSTANCE: combination of powdered haemostatic agents and a biologically active granular sorbent are used topically. First, powdered lyophilizate NovoSeven and zhelplastan are applied on the bleeding ulcerous defect with an insufflator, in equal quantities of 0.1 g each, from a distance of 1.0 cm from the bleeding defect, and then 0.3 g of diovin is insufflated from a distance of 1.5 cm from the ulcerous surface.EFFECT: method allows to increase hemostasis reliability and reduce the time of treatment.1 tbl
ethod for operative hemostasis in acute hardly accessible epidural bleedings from damaged veins, fractures of cranial vault and base and subsequent postoperative supervision // 2633299
FIELD: medicine.SUBSTANCE: epidural hematoma is removed, then the dura mater is pierced and liquid is injected thereunder. At that, a puncture with an insulin needle is performed at an angle of approximately 30-40 degrees to the shell surface, its outer sheet is pierced, then the needle tip is slightly raised. The raised area is grasped with an anatomic tweezers and the insulin needle is further injected under the shell. Physiological solution containing 1-2 ml of cyanocobalamin is then injected into the subdural space in a volume sufficient to completely expand the dura mater and tightly adhere to the edges of the bone defect. Then the insulin needle is removed and an epidural catheter is installed through the hole in the dura mater, the height of the liquid column in which indicates the liquid level under the shell. When the shell stress on the catheter is relaxed, an additional volume of physiological solution containing cyanocobalamin is injected.EFFECT: reduced frequency of hemorrhagic complications decreases, reduced operating injury of skull bones decreases, prevention of the development of the trepanized patients syndrome, minimized risk of hematoma recurrence and the best conditions for subsequent skull plasty are provided, while the hard shell is adapted to the edge of the bone defect.1 ex
ethod for reduction of frequency of intraventricular hemorrhage in newborn in case of early preterm delivery, complicated by non-progressing placental abruption // 2632711
FIELD: medicine.SUBSTANCE: from the first minutes, tranexamic acid therapy is provided during admission to the hospital on 25(0)-27(6) weeks of pregnancy for not progressing placental abruption. Hemostatic therapy for patients is performed in the absence of indications for emergency delivery. Hemostatic therapy with tranexamic acid in case of massive (acute) bleeding is prescribed intravenously dropwise for 250-500 mg at a rate of 5-10 mcg/min - 3-4 times a day. The maximum daily dose is 1000-2000 mg/day. Treatment is carried out until the bleeding stops completely, average - 3-4 days. Supportive therapy is prescribed per os 500 mg 3-4 times a day. The maximum daily dose is 1.5-2.0 g, with an average of 3-4 days.EFFECT: decrease in the frequency of intraventricular hemorrhage in a newborn in case early premature delivery at certain time complicated by non-progressive placental abruption.3 ex
ethod for emergency bleaching and blood crust removal from skin in place of squeezed out acne // 2631593
FIELD: cosmetology.SUBSTANCE: invention is a method of emergency bleaching and blood crust removal from the skin in the place of the squeezed out acne, comprising introduction of a solution of 3% hydrogen peroxide, characterized by additional content of 10% sodium hydrogen carbonate, the solution is pre-applied to a gauze swab area up to the through impregnation, after which the moistened portion of the swab is applied to the selected skin area, pressed firmly against it by the index finger of the dominant hand and moved in the pressed state over the skin surface, wiping by continuous movements of the finger pad for no longer than 5 seconds, after which the swab is removed, the skin under it is visually evaluated, and if traces of pus and blood remain, the swab is applied repeatedly until the pigmented spot acquires the size and shape of the mouth of the wound that appeared at the site of the squeezed out acne.EFFECT: invention provides emergency sanitation, reduction in the pigmented spot area and bleaching of the skin surface at the site of the squeezed out acne under conditions excluding skin coating with pigmented substances and films.1 ex

Hemostatic powders of oxided regenerated cellulose and methods of their production // 2629199
FIELD: chemistry.SUBSTANCE: invention relates to a hemostatic material containing compressed powder of oxidized regenerated cellulose (ORC) produced by grinding in a ball mill. The ORC powder has a bulk density after compaction of, at least, 0.45 g/cm3, fluidity of, at least, 7.5 cm/s. The powder particles have an average size of 1.75 mcm to 116 mcm with a median size of 36 mcm and an average proportionality factor of 1 to 18. The present invention further relates to a method for producing the hemostatic material, a hemostatic paste and the method for treating a wound by applying a hemostatic powder to the patient's wound and/or therein.EFFECT: powder of oxidized regenerated cellulose of the invention is characterized by good adherence, flowability over the tissue and ensures satisfactory placement of powder during surgical procedures.10 cl, 8 dwg, 5 tbl, 9 ex
ethod for coagulopatic bleeding prevention during cesarean section // 2629040
FIELD: medicine.SUBSTANCE: to prevent bleeding during caesarean section, when performing a cut of the anterior abdominal wall during caesarean section, 10 ml of 10% calcium gluconate solution and 10 ml of tranexamic acid containing 1 gram of dry matter are subsequently injected into a peripheral vein.EFFECT: method provides prevention of coagulopathic bleeding with a decrease in perioperative blood loss in patients at risk of such bleeding.8 tbl, 6 ex
Hemostatic sponge and method of its production // 2628809
FIELD: pharmacology.SUBSTANCE: group of inventions is a hemostatic sponge containing a freeze-dried substrate and active substance, characterized in that it contains sodium alginate as the base, and as an active ingredient fibrin monomer with the following ratio of the components in the final aqueous solution in the volume per 1 litre in wt %: Sodium alginate - 0.1-8.0, Fibrin-monomer - 0.01-0.5, as well as a method for obtaining a hemostatic sponge.EFFECT: expansion of the assortment of hemostatic sponges and can be used to stop bleeding in surgical practice, in combat situations, in the aftermath of mass catastrophes and terrorist acts, and in combat situations.4 cl, 13 ex
Treatment of coagulation disease by administration of recombinant vwf // 2628537
FIELD: medicine.SUBSTANCE: group of inventions relates to a method of treating von Willebrand's disease or hemophilia A in a patient in need of treatment comprising administering to the patient a recombinant vWF (vWF) factor so that the half-life of factor VIII is prolonged compared to a patient administered vWF derived from blood plasma, where pFB is not modified with an aqueous soluble polymer. In this case, the pFB is a composition of high molecular weight PV multimers containing at least 20% of the PV emperors or higher-order multimers, with the rVB having a higher specific activity than the vWF derived from the blood plasma. The group of inventions also relates to a method for treating hemophilia A or vWF in a patient in need of treatment that includes administering to the patient a recombinant vWF (vWF) factor, wherein the half-life of FVIII is at least 1.5 times higher than the half-life of FVIII in the patient being treated Von Willebrand factor derived from blood plasma.EFFECT: increase in the half-life of FVIII in the treatment of von Willebrand disease or haemophilia A in the subject.29 cl, 5 ex, 22 dwg, 34 tbl
Hemostatic sponge (versions) // 2627855
FIELD: medicine.SUBSTANCE: invention is a hemostatic sponge containing a base and iron salts as an active substance, characterized by the base and active substance being freeze-dried, while the sponge contains sodium alginate as the base, and iron sulfate as the active ingredient, the components in the sponge are in a certain ratio in the final aqueous solution, in the volume of 1 litre in %.EFFECT: expanded assortment of hemostatic sponges with pronounced hemostatic action and exclusion of direct adverse effect of the active substance on the wound surface and surrounding tissues due to the pharmacological form of the sponge.4 cl, 37 ex

Derivatives of blood coagulation factors vii and viia, conjugates and complexes containing them and their application // 2620072
FIELD: biotechnology.SUBSTANCE: invention relates to production of blood coagulation derivatives VII and VIIa, their conjugates with polymers capable of increasing the half-life of blood from the bloodstream, complexes containing them obtained by carrier binding to the conjugate, to genes encoding the derivatives, to expression vectors containing these genes, transformants with introduced expression vectors, to methods for their preparation, pharmaceutical compositions and treatment methods, and can be used in medicine to prevent or treat hemophilia or to improve blood coagulation. A FVII derivative is obtained which is linked at its C-terminus to the peptide linker for binding to a non-peptidyl polymer capable of increasing the half-life of FVII or FVIIa from the blood stream. At that, the peptide linker is a partial sequence of superoxide dismutase SOD1, its mutated sequence or GGGGSC sequence.EFFECT: invention allows to obtain an FVII derivative capable of binding to a carrier increasing the half-life from the blood stream while maintaining FVII activity.42 cl, 8 dwg, 3 tbl, 8 ex

ultispecific antigen-binding molecule with alternate function to blood coagulation factor viii function // 2620071
FIELD: biotechnology.SUBSTANCE: invention relates to a bispecific antibody that binds to both blood coagulation factor IX/activated blood coagulation factor IX, and blood coagulation factor X, and functionally replaces blood coagulation factor VIII. This invention discloses the nucleic acid encoding the said bispecific antibody, a vector, a cell and a method for antibody production, as well as a pharmaceutical composition and a kit for use in the method for prevention and/or treatment of bleeding or diseases associated with or caused by bleeding.EFFECT: invention may find further application for treatment of diseases associated with impaired blood clotting, such as acquired hemophilia and von Willebrand disease.17 cl, 6 dwg, 2 ex
Haemostatic sponge and method for its preparation // 2618896
FIELD: pharmacology.SUBSTANCE: invention is a haemostatic sponge containing a base and an active substance, freeze-dried. According to the invention, the sponge, contains chitosan in acetic acid as the base and a fibrin monomer as the active substance, the components in the spongeare at a certain ratio in % by 1 litre volume.EFFECT: expansion of haemostatic sponges assortment based on a chitosan and fibrin-monomer complex with pronounced haemostatic action.4 cl, 13 ex
ethod to stop gastroduodenal bleeding // 2618406
FIELD: medicine.SUBSTANCE: combination of a powdered haemostatic agent and a biologically active granular sorbent is used topically. Therapeutic endoscopy is carried out, during which 0.2 g of powdered polygemostat is first applied to the bleeding defect via a pneumoinsufflator from a distance of 1.5 cm from the defect, and then 0.4 g of anilodiovin is insufflated from a distance of 2.0 cm from the defect to cover the entire bleeding surface.EFFECT: method allows to increase hemostasis reliability and reduce the time of treatment.1 tbl, 2 ex
ethod for primary sclerogenic preventive hemostasis at esophagus and stomach varicose veins bleeding height // 2617108
FIELD: medicine.SUBSTANCE: method comprises intravasal administration of Aethoxysklerol microfoam to the esophageal vein lumen. Microfoam is prepared by 3% Aethoxysklerol mixing with air at a ratio of 1:6 or 1% Aethoxysklerol mixing with air at a ratio of 2:6. The resulting 7-8 ml of Aethoxysklerol microfoam is introduced into the esophageal or stomach bleeding vein lumen via an injector 1.5 cm proximal to the bleeding source. If necessary, injections are repeated in other veins, further 2 ml of 1% hydrogen peroxide solution is administered paravasally submucosally at the cardia level from each side of the vein. Hemostasis is monitored after 8-12 hours, if necessary, the procedure is repeated after 6 days, 1, 3, 6 months.EFFECT: method allows to effectively stop bleeding from varicose veins with simultaneous sclerotherapy, providing prevention of bleeding, is easy to use and safe.6 dwg, 1 ex
Factor ii and fibrinogen for treatment of haemostatic disorders // 2606155
FIELD: medicine.SUBSTANCE: present group of inventions relates to medicine, namely to haematology and can be used for normalising impaired haemostasis. Methods include administering a clotting factor treatment consisting of FII, PCC and a three factor combination of FII, FX and FVIIa or fibrinogen and FII.EFFECT: use of these inventions enables to reduce the risk of thromboembolic complications.24 cl, 12 dwg, 2 ex

ethod of producing fibrinogen using strong anion exchange resin and fibrinogen-containing product // 2603103
FIELD: biotechnology.SUBSTANCE: group of inventions relates to biotechnology. Invention discloses a method of purifying fibrinogen, a fibrinogen-containing product and use of an anion-exchange resin, containing a hydroxylated methacrylic polymer with trimethylamino groups grafted through binding group, for producing said product using said method. Fibrinogen-containing source undergoes chromatography on anion-exchange resin based on hydroxylated methacrylate polymer with trimethylamino groups grafted through binding group. Fibrinogen-containing product is obtained, having high degree of purity without content of viruses and prions with content of fibronectin of 0.01-1.00 mcg/mg of fibrinogen, fibrinopeptide A 0.01-9.0 ng/mg of fibrinogen, with activity vWF: Ag less than 0.1 IU/mg of fibrinogen, with activity of factor XIII 0.07-1.0 IU/mg of fibrinogen and thrombin activity less than 0.007 IU/mg of fibrinogen.EFFECT: invention discloses a method of purifying fibrinogen, a fibrinogen-containing product and use of an anion-exchange resin, containing a hydroxylated methacrylic polymer with trimethylamino groups grafted through binding group, for producing said product using said method.18 cl, 5 tbl

Hemostatic agent // 2602305
FIELD: medicine.SUBSTANCE: invention refers to medicine and consists in hemostatic preparation that represents polyimmunomethanediamine chloride.EFFECT: technical result consists in effective hemostatic action with provision of evident pain relief.22 cl, 2 ex, 30 tbl

Biodegradable non-woven material for medical purposes // 2596502
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine, more specifically to a biodegradable non-woven material containing (i) at least one polymer for inducing primary haemostasis, (ii) at least one non-proteinogenic, water-soluble secondary haemostasis activator at (iii) least one non-proteinogenic, water-soluble fibrinolysis inhibitor. Method for producing a biodegradable non-woven material is described, wherein (i) a fluidised raw fibre material is placed in a container, optionally along with additives, (ii) container is set in rotation, (iii) fluidised raw fibre material is discharged from the container by means of centrifugal forces, as a result of which fibres or filaments are formed, and (iv) a biodegradable non-woven material is formed from the fibres or filaments.EFFECT: use of biodegradable non-woven material formed so that human fibroblasts can penetrate into non-woven material and so that the connective tissue can form in the course of wound healing.13 cl, 4 dwg, 3 ex

Phospholipid-enriched vesicles bearing tissue factor having haemostatic activity and use thereof // 2595406
FIELD: biotechnology.SUBSTANCE: present invention relates to a method of improving procoagulant properties of tissue factor (TF) expressed in eukaryotic cells, and can be used in medicine. Modified tissue factor bearing microvesicle produced in accordance with present invention can be used as procoagulant agent for treating bleeding, wound healing and stimulating angiogenesis in tissues.EFFECT: invention improves procoagulant properties of tissue factor due to that obtained TF bearing microvesicle is generated from lipid membranes or their fragments of eukaryotic cells, in which tissue factor is expressed, as well as additional additive of negatively charged phospholipid.18 cl, 16 dwg, 2 tbl, 5 ex

ethod and apparatus for producing serum with thrombin from one donor // 2589648
FIELD: medicine.SUBSTANCE: group of inventions relates to transfusion medicine. Serums with thrombin are produced. For this purpose liquid blood sample is obtained, having first aliquot of liquid blood with procoagulant to make prothrombinaze enzyme complex associated with surface of procoagulant agent, which enables to obtain activated procoagulant agent, which can be stored. Activated procoagulant agent then may be subjected to interaction with second liquid blood aliquot containing prothrombin to obtain serum with Thrombin, which can be extracted and subjected to interaction with fibrinogen for preparing fibrin. To obtain serum with Thrombin special device is used containing reaction chamber with one or several compartments to hold procoagulant agent and liquid part of blood without flow. Procoagulant agent can reaction with said liquid part of blood to form fibrin gel, appliances to feed fluid into and from reaction chamber, means to retain solid particles in reaction chamber; agent for serum separation with Thrombin from fibrin gel. Further, device also comprises ventilation hole made with possibility of avoiding long period of staying under excessive pressure of reaction chamber. At that, one or several solid floating objects are present in reaction chamber, wherein solid loose objects, have diameter within range of 50 mcm and 2 mm, and other solid loose objects are characterised by dimensions selected for grinding of fibrin gel, and in cross section have, at least 4 mm.EFFECT: group of inventions allows eliminating risk of toxic reaction in patient in response to introduction of serum with Thrombin, risk of immunogenic reactions and risk of infectious diseases transmission from donors.25 cl, 8 dwg, 2 tbl

Pletnev drops possessing coagulating agent action, and method of treating thrombocytopenia in hepatic diseases and leukaemia // 2589260
FIELD: medicine.SUBSTANCE: invention relates to drops possessing coagulating action. Drops represent 95 % ethyl alcohol infusion of great nettle leaves and common motherwort grass, taken at ratio of 1:9 to 9:1, with 250-450 mcg substance content in 1 ml of infusion. Present invention also relates to method of treating thrombocytopenia in hepatic diseases and leukaemia, involving peroral introduction of said drops to patient.EFFECT: invention promotes normalisation of platelet content in blood volume unit.2 cl, 2 tbl, 2 ex

Haemostatic preparation containing extract of golden moss // 2581918
FIELD: pharmaceutics.SUBSTANCE: present invention refers to pharmaceutical industry, namely to haemostatic preparation for local application. Semi-liquid haemostatic preparation for local application, containing: extract of Golden Moss rootstock, which is based on extract ethanol or is aqueous extract, gelatine and physiologic saline. Method of haemostatic treatment point bleeding, involving the stages of preparing semi-liquid haemostatic preparation and application of its back bleeding. Method of making semi-liquid haemostatic preparation containing: boiling Golden Moss roots in solvent, which is ethanol or water, removing essentially entire solvent by evaporation under vacuum conditions to produce extract Golden Moss, and mixing extract Golden Moss with normal saline and powder gelatine.EFFECT: haemostatic preparation described above is effective.14 cl, 2 dwg, 1 tbl, 4 ex

8-azabicyclo[3,2,1]octan-8-carboxamide derivative // 2574597
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to compounds of formula and their pharmaceutically acceptable salts having the property of 11β dehydrogenase hydroxysteroid type 1 (11βHSD1) inhibitor, based medicinal and therapeutic agents, a method for prevention or treatment with using them, and using them for treating 11βHSD1-mediated diseases, such as type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, insulin resistance, lipid dismetabolism, hypertension, arterial sclerosis, angiosclerosis, etc. In formula (1) A represents a group, which is presented by formula ; R1a and R1b are identical or different, and each independently represents C1-6 alkyl, which can be optionally substituted by 1-3 halogen atoms; each of m and n independently represents an integer from 0 to 5; X1 represents hydroxyl or aminocarbonyl; Z1 represents a single bond, oxygen atom, sulphur atom, -SO-, -SO2- or -N(R3)-; R2 represents optionally substituted C1-6 alkyl, optionally substituted C3-7 cycloalkyl, optionally substituted C6-10 aryl, optionally substituted C7-16 aralkyl, optionally substituted 3-7-merous heterocycle, optionally substituted 3-7-merous heterocyclic C1-6 alkyl, optionally substituted 5-12-merous mono- or polycyclic heteroaryl, optionally substituted 5-12-merous mono- or polycyclic heteroaryl-C1-6 alkyl, or optionally substituted 5-7-merous cyclic amino group; R3 represents C1-6 alkyl, C3-7 cycloalkyl, C6-10 aryl, or C7-16 aralkyl; or its pharmaceutically acceptable saly.EFFECT: producing the pharmacologically acceptable salts possessing the property of 11β hydroxysteroid dehydrogenase type 1 (11βHSD1) inhibitor.42 cl, 47 tbl, 438 ex

Conjugated factor viii molecules // 2573587
FIELD: chemistry.SUBSTANCE: invention relates to field of biotechnology, namely to obtaining B-domain truncated factor VIII molecule and covalently conjugated with hydrophilic polymer, which has altered half-life in bloodstream, and can be used in medicine to treat haemophilia. Molecule of precursor of B-domain truncated factor VII, where B-domain corresponds to amino acids 741-761 from SEQ ID NO 2, is obtained. Said molecule is covalently conjugated with PEG or polysaccharide with size 10-80 kDa by means of O-linked oligosaccharide at serine residue in truncated B-domain, which corresponds to amino acid 750 in SEQ ID NO 2.EFFECT: invention makes it possible to increase factor VIII half-life in bloodstream.8 cl, 8 dwg, 4 tbl, 7 ex

odified factor vii-based polypeptides and thereof application // 2571931
FIELD: chemistry.SUBSTANCE: invention relates to field of biotechnology, namely to obtaining modified factor FVII, and can be used in medicine. Polypeptide FVII is modified by substitution of amino acid residue, selected from D196L, D196I, D196Y, K197E, K197D, K197L, K197M, K197I, K197V, K197F, K197W, K197Y, K199D and K199E, in amino acid sequence FVII, represented as SEQ ID NO: 3, or in respective residues of its precursor with SEQ ID NO: 1 or SEQ ID NO: 2. Polypeptide can contain additional modifications of amino acids, which improve its functional properties.EFFECT: invention makes it possible to obtain modified polypeptide FVII, which, when activated, possesses increased coagulant activity and/or increased resistance to inhibitors in comparison with non-modified polypeptide FVII with sequence, given in SEQ ID NO: 3.48 cl, 7 dwg, 23 tbl, 17 ex

Compositions and methods for haemostasis modulation // 2570547
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to biochemistry, particularly to haemostasis-enhancing variants of factor Xa, nucleic acids coding them, producing and using factor Xa for treating haemostasis-related disorders. The declared factor Xa contains an amino acid sequence in a sequence of wild-type factor X in position 16, 17 or 194 in a chymotrypsin numbering system.EFFECT: invention enables the haemostasis enhancement effectively.21 cl, 11 dwg, 5 tbl, 1 ex

Organic amine salts of aminobenzoic acid and method for obtaining thereof // 2569885
FIELD: chemistry.SUBSTANCE: invention relates to organic amine salt or salt with quaternary ammonium ion of 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3- thienyl]ethyliden}hydrazino)carbonothioyl]amino}benzoic acid, possessing useful properties, which increases the number of platelets.EFFECT: obtaining compounds, possessing useful properties, increasing the number of platelets.16 cl, 4 tbl, 4 ex
ethod for haemostasis accompanying surgical treatment of foot ulcers in diabetic patients // 2567788
FIELD: medicine.SUBSTANCE: ulcerous defect is surgically treated. If observing a haemorrhage during the surgical treatment, a bleeding area is coated with 1.5-2.5 g of Polygemostat preparation with a sterile gauze swab applied for 5-10 seconds. The ulcerous defects are treated until repaired.EFFECT: method provides fast and effective haemostasis during the surgical treatment of ulcerous defects, prevents recurrent haemorrhages over a period of treatment of the patients suffering a diabetic foot syndrome, accelerates regeneration processes ensured by pharmacological effects of the used preparation, including its antiseptic and healing properties.
ethod of producing haemostatic agent based on oxidised cellulose using microwave action (versions) // 2563279
FIELD: chemistry.SUBSTANCE: invention provides two versions of a method of producing a haemostatic agent based on oxidised cellulose under the effect of microwave radiation. Version 1 is carried out as follows: oxidising a medical gauze with nitrogen dioxide solution in an inert solvent, the oxidation being carried out under the effect of 70-100 W microwave radiation for 4-5 hours at 40-50°C, wherein the vessel is constantly cooled with an external air current; the solution is then removed in a vacuum created by a water-jet pump; the oxidised tissue is washed and dried. Version 2 is carried out as follows: oxidising powdered cellulose with nitrogen dioxide solution in an inert solvent, the oxidation being carried out under the effect of 60-100 W microwave radiation for 1-5 hours at 40-50°C while stirring, wherein the reaction vessel is constantly cooled with an external air current; the solution is then decanted removed in a vacuum created by a water-jet pump; the oxidised powdered cellulose is then washed and dried.EFFECT: faster cellulose oxidation and, as a result, the process of producing a haemostatic agent based on oxidised cellulose, obtaining oxidised cellulose with high content of carboxyl groups.13 cl, 3 tbl

Von willebrand factor or factor viii and von willebrand factor for treatment of coagulopathy, induced by platelet inhibitors // 2563236
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to the field of pharmaceutics and medicine and deals with the application of the von Willebrand factor in a combination with factor VIII for the treatment and/or prevention of a haemorrhage episode, associated with thrombopathy, induced with platelet-inhibiting substances, the where platelet-inhibiting substance is represented by an inhibitor of ADP receptor or a combination of the inhibitor of FDP receptor and cyclooxygenase inhibitor. The invention also relates to a composition and a method of treatment and/or prevention of a disorder, associated with the haemorrhage, associated with thrombopathy, induced by the platelet-inhibiting substances.EFFECT: group of inventions provides the reduction or prevention of undesirable instances of the haemorrhage after the introduction of anticoagulants or fibrinolytics.19 cl, 6 dwg, 5 tbl, 2 ex

Factor vii chimeric molecules // 2563231
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to medicine, namely to haematology and can be applied in treatment of disorders, associated with haemorrhage. Method in accordance with invention includes introduction of factor VIIa chimeric polypeptide to subject, where said factor VIIa chimeric polypeptide includes domain EGF-2 and factor VII catalytic domain; GLA domain, selected from the group, consisting of factor VII GLA domain, factor IX GLA domain and protein S GLA domain; and EGF-1 domain, selected from the group, consisting of factor IX EGF-1 domain and protein S EGF-1 domain. Factor VIIa chimeric polypeptide in accordance with invention includes EGF-2 domain and factor VII catalytic domain; protein S GLA domain; and EGF-1 domain, selected from the group, consisting of protein S EGF-1 domain and factor IX EGF-1 domain. Molecule of nucleic acid by invention codes factor VIIa chimeric polypeptide. Inventions also deal with vector, including molecule of nucleic acid, cell, including factor VIIa chimeric polypeptide and cell, including vector.EFFECT: application of inventions makes it possible to reduce doses of introduced protein and attenuate undesirable side effects.11 cl, 7 dwg, 5 ex

edical absorable haemostatic material for osteal wounds and method for producing // 2557917
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine. What is described is a medical absorbable haemostatic and wound healing material for osteal wounds and a method for producing it. The absorbable haemostatic material for osteal wounds contains 40-95% of a primary material and 5-60% of an auxiliary on the basis of weight percentage, wherein the primary material contains an oligosaccharide, a polysaccharide or a mixture of the oligosaccharide and polysaccharide, while the auxiliary contains (1) one or more polyatomic alcohols, (2) one or more emulsifiers. The method for producing the absorbable haemostatic and wound healing material for osteal wounds consists of the following stages involving mixing the primary material and auxiliary in the pre-set amounts by chemical mixture and preparation of the mixture at the stage of latex, and cooling to form a solid piece, packaging and sterilising.EFFECT: material is degradable in the body and promotes osteal wound healing.7 cl, 4 tbl, 9 ex

ethod of preventing bleeding caused by use of streptokinase in experiment // 2552339
FIELD: veterinary medicine.SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injection is added to the lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin monomer at a concentration of 11 mg/ml and urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. At that the dose of fibrin-monomer is 0.25 mg/kg.EFFECT: method is highly effective the prevention of bleeding caused by the use of streptokinase, prior to surgical interferences.1 ex, 2 dwg

ethod of prevention of bleeding caused by use of dabigatran etexilate in experiment // 2552331
FIELD: veterinary medicine.SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injections is added to lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin-monomer at a concentration of 11 mg/ml and the urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. The dose of fibrin-monomer is 0.25 mg/kg.EFFECT: method is highly effective for prevention of bleeding caused by the use of dabigatran etexilate in the experiment.2 dwg, 1 ex

Pharmaceutical compositions and respective delivery methods // 2552324
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to medicine and deals with pharmaceutical composition, containing suspension, which includes mixture of hydrophobic medium and solid form, where solid form contains therapeutically effective quantity of octreotide and, at least, one salt of fatty acid with medium chain length, which has chain length from 6 to 14 carbon atoms, and matrix-forming polymer, selected from dextran and polyvinylpyrrolidone (PVP), with salt of fatty acid with medium chain length being present in composition in amount of 10% by weight or more. Group of inventions also deals with capsule, containing said composition, intended for peroral introduction; method of obtaining said pharmaceutical composition.EFFECT: group of inventions relates to improvement of octreotide bioavailability.100 cl, 39 ex, 10 dwg, 45 tbl

Haemostatic medication based on synthetic tripeptide plasmin inhibitor // 2550945
FIELD: medicine.SUBSTANCE: medication based on tripeptide Ac-Ala-Phe-Lys-Pip·AcOH or its pharmaceutically acceptable salts is applied. The claimed medication can be made in the form of a solution, gel, plate or sponge.EFFECT: application of the said medication makes it possible to considerably reduce the volume of haemorrhage and reduce the time of bleeding stopping due to high anti-plasmin activity of the tripeptide Ac-Ala-Phe-Lys-Pip·AcOH with the absence of side effects.2 cl, 8 ex, 2 tbl

ethod for control of bleedings accompanying perforating wound of liver // 2550284
FIELD: medicine.SUBSTANCE: wound canal is packed with a preparation of recovered oxygenated cellulose. Thereafter in an entrance wound, the preparation is exposed to 2 cycles of cryotherapy with liquid nitrogen at a temperature of minus 196°C for 1-2 minutes until an ice crust is formed on the wound surface.EFFECT: method provides excluding the possibility of bleeding and bile flowing from an inner surface of stab wounds, reducing a risk of recurrent bleedings, formation of liver haematomas postoperatively.3 dwg, 2 tbl, 2 ex

Haemostatic agent // 2545991
FIELD: medicine.SUBSTANCE: invention relates to medicine and veterinary and is intended for the acceleration of stopping bleeding in case of injury to blood vessels in traumas and wounds. A haemostatic agent contains 3-20 wt % of a polysaccharide, where the polysaccharide is represented by chitosan and/or starch, 0.1-2 wt % of calcium chloride and a 0.5-5% water solution of succinic or hydrochloric acid - the remaining part.EFFECT: accelerating the initiation of the thrombus-forming process and enhancement of the regenerative ability of tissues in the area of wounds of different aetiology.1 tbl, 14 ex

Bicyclosubstituted azopyrazolone derivatives salts, method for preparing and using them // 2538977
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutically acceptable salts specified in a group consisting of sodium salt, lithium salt, potassium salt, calcium salt, magnesium salt, arginine salt, lysine salt, methanamine salt, dimethylamine salt, trimethylamine salt, ethylamine salt, diethylaminte salt, triethylamine salt, ethanolamine salt, piperazine salt, dibenzylethylene diamine salt, methyl glucamine salt, tromethamine salt, quaternary tetramethylammonium salt, quaternary tetraethylammonium salt and choline salt, bicyclosubstituted azopyrazole derivatives of general formula . The invention also refers to a method for preparing them, a pharmaceutical composition containing them, and using them as a therapeutic agent, particularly as thrombopoietin (TPO) mimetics, using them as TPO agonists. In general formula (I), Het is specified in a group consisting of phenyl, furanyl and thienyl; each R1, R2, R3 andR4 are independently specified in a group consisting of hydrogen and alkyl; n is equal to 0, 1 or 2.EFFECT: improving the pharmokinetic properties of the compound of formula (I) ensured by better solubility.19 cl, 1 tbl, 25 ex

ultispecific antigen-binding molecule that has alternate function to function of blood coagulation factor viii // 2534564
FIELD: biotechnology.SUBSTANCE: bispecific antibody is proposed, that binds to both the blood coagulation factor IX/activated blood coagulation factor IX and with the blood coagulation factor X, and functionally replaces the function of blood coagulation factor VIII. The nucleic acid is considered, encoding the antibody of the invention, a vector, a cell and a method of producing the antibody, and also a pharmaceutical composition and a kit for use in the method of preventing and/or treating bleeding or diseases associated with or caused by bleeding.EFFECT: invention may find further application in the treatment of diseases associated with impaired blood clotting.16 cl, 2 ex, 6 dwg

ultispecific antigen-binding molecule, possessing alternative function to function of blood coagulation factor viii // 2534347
FIELD: chemistry.SUBSTANCE: claimed is bispecific antibody, which is bound with both blood coagulation factor IX/activated blood coagulation factor IX and with blood coagulation factor X and functionally replaced function of blood coagulation factor VIII. Described are nucleic acid, coding antibody by invention, vector, cell and method of obtaining antibody, as well as pharmaceutical composition and set for application in method of prevention and/or treatment of bleeding or diseases, associated with or induced by bleeding.EFFECT: invention can be applied in therapy of diseases, associated with blood coagulation disorders.16 cl, 2 ex, 6 dwg
ethod of treating endogenous intoxication syndrome caused by hyperproteolysis // 2524647
FIELD: medicine.SUBSTANCE: antiproteolytic preparation Ambene in a dose of 50-250 mg is introduced intravenously by the stream infusion for at least three days every 3-4 hours in a combination with heparin. Heparin is introduced subcutaneously is a dose of 250 units 4 times a day.EFFECT: effective treatment of endogenous intoxication syndrome caused by proteolysis by blocking fibrinolysis and enhancing the detoxifying and anti-inflammatory action of Ambene.2 tbl, 2 ex
Biodegradable haemostatic therapeutic agent // 2522980
FIELD: medicine.SUBSTANCE: what is described is a biodegradable haemostatic therapeutic agent for control of bleeding, which provides co-immobilising ε-aminocapronic acid 50 mg, lysozyme 5 mg in distilled water 6.5 l for 3 hours at room temperature for dialdehyde cellulose 1 g at a degree of oxidation 12%. The material is pressed out and dried to residual moisture no more than 10% in the air in darkness. After having dried, the material is milled in a fine mill to particles having a size of 20 to 50 mcm. A rate of control of bleeding is 102 seconds. A time of total resorption is 10 days.EFFECT: agent provides a high degree of hydrolytic destruction and a good haemostatic activity.4 cl, 2 ex
Biodegradable haemostatic therapeutic agent for control of capillary and parenchymatous bleedings // 2522879
FIELD: medicine.SUBSTANCE: invention represents a biodegradable haemostatic therapeutic agent for bleeding. Using the prepared haemostatic agent according to the declared method provides a rate of control of bleeding making 45±2 seconds.EFFECT: higher rate of control of bleeding.4 cl, 2 tbl
Local hemostatic agent // 2522206
FIELD: chemistry.SUBSTANCE: agent further contains aluminium and/or magnesium oxides and satisfies the formula: CaO·(SiO2)m·(M)n·(H2O)k, where M is Al2O3 and/or MgO; m=0.5-3.0; n=0.01-0.05; k=0.2-1.2.EFFECT: shorter time for onset of hemostasis and low exothermic effect during interaction with blood.2 tbl, 9 ex
 
2551024.
Up!